🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

18+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 18 of 18 recruiting trials for “thymic-carcinoma

Phase 2RecruitingNCT06790706

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

🏥 Hospices Civils de Lyon📍 15 sites📅 Started Oct 2025View details ↗
NARecruitingNCT07029152

Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis

🏥 Universitair Ziekenhuis Brussel📍 7 sites📅 Started Sep 2025View details ↗
Phase 1RecruitingNCT06902376

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

👨‍⚕️ Siddharth Sheth, DO MPH, UNC Lineberger Comprehensive Cancer Center📍 2 sites📅 Started Jun 2025View details ↗
Phase 2RecruitingNCT06302569

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

👨‍⚕️ Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT06640283

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

👨‍⚕️ Maria DP Estevez Diz, Doctor, Oncologist📍 1 site📅 Started Mar 2025View details ↗
NARecruitingNCT06792604

Host Genome Methylation: a Screening Tool in Anal Cancer Detection

🏥 Assistance Publique - Hôpitaux de Paris📍 9 sites📅 Started Nov 2024View details ↗
Phase 2RecruitingNCT06235216

Sacituzumab govitEcan in THYroid Cancers

👨‍⚕️ Alejandro García-Alvarez, M.D.; Ph.D., Hospital Universitario Vall d´Hebron📍 11 sites📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06374602

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

🏥 Saint Petersburg State University, Russia📍 1 site📅 Started Mar 2024View details ↗
Phase 2RecruitingNCT06362694

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

🏥 Saint Petersburg State University, Russia📍 1 site📅 Started Mar 2024View details ↗
Phase 3RecruitingNCT06207981

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

👨‍⚕️ Veronique Vendrely, Md-pHD, University Hospital, Bordeaux📍 114 sites📅 Started Feb 2024View details ↗
Phase 2RecruitingNCT06211114

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

👨‍⚕️ Xinan Sheng, MD., Peking University Cancer Hospital & Institute📍 2 sites📅 Started Feb 2024View details ↗
Phase 2RecruitingNCT06007924

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

👨‍⚕️ Alan Ho, MD, PhD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Aug 2023View details ↗
Phase 2RecruitingNCT05661188

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)

👨‍⚕️ Jaume Capdevila, Hospital Vall d'Hebron📍 15 sites📅 Started Feb 2023View details ↗
Phase 2RecruitingNCT06079333

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

👨‍⚕️ Ellen Kapiteijn, MD, PhD, Leiden University Medical Center📍 1 site📅 Started Jan 2023View details ↗
RecruitingNCT06327568

Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens

🏥 European Institute of Oncology📍 1 site📅 Started Jun 2022View details ↗
RecruitingNCT05438836

Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

👨‍⚕️ Eva S Serup-Hansen, MD, PhD, Herlev og Gentofte Hospital📍 1 site📅 Started Jan 2022View details ↗
Phase 1RecruitingNCT03975231

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

👨‍⚕️ Sasan Fazeli, MD, City of Hope Medical Center📍 3 sites📅 Started Sep 2020View details ↗
RecruitingNCT03765333

GETNE Registration of Thyroid Cancer

👨‍⚕️ Jorge Hernando Cubero, M.D., Hospital Universitari Vall d'Hebron, Barcelona📍 1 site📅 Started May 2019View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →